WPI 844 (Glipizide Extended Release 5 mg)

Pill with imprint WPI 844 is Orange, Round and has been identified as Glipizide Extended Release 5 mg. It is supplied by Watson Laboratories, Inc..

Glipizide is used in the treatment of diabetes, type 2 and belongs to the drug class sulfonylureas. Risk cannot be ruled out during pregnancy. Glipizide 5 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for WPI 844

Glipizide extended release 5 mg WPI 844 Front

Glipizide Extended Release

Imprint: WPI 844
Strength: 5 mg
Color: Orange
Size: 6.00 mm
Shape: Round
Availability: Prescription only
Drug Class: Sulfonylureas
Pregnancy Category: C - Risk cannot be ruled out
CSA Schedule: Not a controlled drug
Labeler / Supplier: Watson Laboratories, Inc.
Inactive Ingredients: acetyltributyl citrate, ammonia, butyl alcohol, ferrosoferric oxide, hydroxyethyl cellulose (2000 cps at 1%), isopropyl alcohol, lactose monohydrate, magnesium stearate, methacrylic acid - methyl methacrylate copolymer (1:1), polyethylene glycol 400, propylene glycol, shellac, FD&C Yellow No. 6
Note: Inactive ingredients may vary.

Labelers / Repackagers

NDC Code	Labeler / Repackager
00591-0844	Watson Pharmaceuticals, Inc.
68084-0111	Amerisource Health Services
10370-0190	Anchen Pharmaceuticals, Inc.
54569-5547	A-S Medication Solutions, LLC (repackager)
54868-5210	Physicians Total Care Inc. (repackager)